Researchers have uncovered a crucial role of a cell surface protein called Aplp1 in spreading the material responsible for Parkinson’s disease between brain cells. Promisingly, an FDA-approved cancer drug that targets another protein, Lag3, which interacts with Aplp1, has been shown to block this spread in mice, suggesting a potential therapy may already exist.
In a new study, an international team of scientists describes how Aplp1 and Lag3 work together to facilitate the entry of harmful alpha-synuclein protein clumps into brain cells.
Continue reading… “Discovery of Key Proteins and Potential Treatment Pathway for Parkinson’s Disease”
